vs

Side-by-side financial comparison of Canterbury Park Holding Corp (CPHC) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.

Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $12.4M, roughly 1.8× Canterbury Park Holding Corp). Canterbury Park Holding Corp runs the higher net margin — -3.1% vs -416.2%, a 413.0% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 3.9%). Canterbury Park Holding Corp produced more free cash flow last quarter ($-611.3K vs $-69.4M). Over the past eight quarters, Canterbury Park Holding Corp's revenue compounded faster (-6.0% CAGR vs -10.8%).

Canterbury Park, is a horse racing track in Shakopee, Minnesota, United States. Canterbury Park Holding Corporation hosts parimutuel wagering on live thoroughbred and quarter horse racing at its facilities in Shakopee and parimutuel wagering on races held at out-of-state racetracks that are simulcast to the racetrack. In addition, the Canterbury Park Card Casino operates 24 hours a day, seven days a week, and is also regulated by the Minnesota Racing Commission. Casino games include blackjack...

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...

CPHC vs NTLA — Head-to-Head

Bigger by revenue
NTLA
NTLA
1.8× larger
NTLA
$23.0M
$12.4M
CPHC
Growing faster (revenue YoY)
NTLA
NTLA
+74.9% gap
NTLA
78.8%
3.9%
CPHC
Higher net margin
CPHC
CPHC
413.0% more per $
CPHC
-3.1%
-416.2%
NTLA
More free cash flow
CPHC
CPHC
$68.8M more FCF
CPHC
$-611.3K
$-69.4M
NTLA
Faster 2-yr revenue CAGR
CPHC
CPHC
Annualised
CPHC
-6.0%
-10.8%
NTLA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CPHC
CPHC
NTLA
NTLA
Revenue
$12.4M
$23.0M
Net Profit
$-390.1K
$-95.8M
Gross Margin
Operating Margin
2.6%
-428.9%
Net Margin
-3.1%
-416.2%
Revenue YoY
3.9%
78.8%
Net Profit YoY
68.7%
25.7%
EPS (diluted)
$-0.08
$-0.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CPHC
CPHC
NTLA
NTLA
Q4 25
$12.4M
$23.0M
Q3 25
$18.3M
$13.8M
Q2 25
$15.7M
$14.2M
Q1 25
$13.1M
$16.6M
Q4 24
$12.0M
$12.9M
Q3 24
$19.3M
$9.1M
Q2 24
$16.2M
$7.0M
Q1 24
$14.1M
$28.9M
Net Profit
CPHC
CPHC
NTLA
NTLA
Q4 25
$-390.1K
$-95.8M
Q3 25
$487.3K
$-101.3M
Q2 25
$-327.4K
$-101.3M
Q1 25
$-299.2K
$-114.3M
Q4 24
$-1.2M
$-128.9M
Q3 24
$2.0M
$-135.7M
Q2 24
$338.3K
$-147.0M
Q1 24
$998.2K
$-107.4M
Operating Margin
CPHC
CPHC
NTLA
NTLA
Q4 25
2.6%
-428.9%
Q3 25
5.7%
-808.9%
Q2 25
2.8%
-772.2%
Q1 25
4.9%
-726.6%
Q4 24
-0.8%
-1059.9%
Q3 24
18.9%
-1589.0%
Q2 24
6.9%
-1998.6%
Q1 24
12.5%
-394.0%
Net Margin
CPHC
CPHC
NTLA
NTLA
Q4 25
-3.1%
-416.2%
Q3 25
2.7%
-735.2%
Q2 25
-2.1%
-710.8%
Q1 25
-2.3%
-687.6%
Q4 24
-10.4%
-1001.2%
Q3 24
10.5%
-1489.5%
Q2 24
2.1%
-2112.6%
Q1 24
7.1%
-371.3%
EPS (diluted)
CPHC
CPHC
NTLA
NTLA
Q4 25
$-0.08
$-0.81
Q3 25
$0.10
$-0.92
Q2 25
$-0.06
$-0.98
Q1 25
$-0.06
$-1.10
Q4 24
$-0.25
$-1.27
Q3 24
$0.40
$-1.34
Q2 24
$0.07
$-1.52
Q1 24
$0.20
$-1.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CPHC
CPHC
NTLA
NTLA
Cash + ST InvestmentsLiquidity on hand
$17.1M
$449.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$83.9M
$671.4M
Total Assets
$112.6M
$842.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CPHC
CPHC
NTLA
NTLA
Q4 25
$17.1M
$449.9M
Q3 25
$16.7M
$511.0M
Q2 25
$16.9M
$459.7M
Q1 25
$15.4M
$503.7M
Q4 24
$15.1M
$601.5M
Q3 24
$21.7M
$658.1M
Q2 24
$23.8M
$691.1M
Q1 24
$25.2M
$791.3M
Stockholders' Equity
CPHC
CPHC
NTLA
NTLA
Q4 25
$83.9M
$671.4M
Q3 25
$84.1M
$748.4M
Q2 25
$83.6M
$715.3M
Q1 25
$83.7M
$779.9M
Q4 24
$84.1M
$872.0M
Q3 24
$85.2M
$962.6M
Q2 24
$83.2M
$971.1M
Q1 24
$82.7M
$1.0B
Total Assets
CPHC
CPHC
NTLA
NTLA
Q4 25
$112.6M
$842.1M
Q3 25
$114.4M
$925.3M
Q2 25
$114.9M
$898.9M
Q1 25
$112.4M
$986.2M
Q4 24
$109.9M
$1.2B
Q3 24
$114.2M
$1.2B
Q2 24
$111.4M
$1.2B
Q1 24
$105.6M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CPHC
CPHC
NTLA
NTLA
Operating Cash FlowLast quarter
$-103.4K
$-69.3M
Free Cash FlowOCF − Capex
$-611.3K
$-69.4M
FCF MarginFCF / Revenue
-4.9%
-301.6%
Capex IntensityCapex / Revenue
4.1%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.7M
$-395.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CPHC
CPHC
NTLA
NTLA
Q4 25
$-103.4K
$-69.3M
Q3 25
$1.2M
$-76.9M
Q2 25
$4.4M
$-99.6M
Q1 25
$3.4M
$-148.9M
Q4 24
$-2.8M
$-85.2M
Q3 24
$2.3M
$-84.8M
Q2 24
$5.4M
$-58.2M
Q1 24
$1.6M
$-120.7M
Free Cash Flow
CPHC
CPHC
NTLA
NTLA
Q4 25
$-611.3K
$-69.4M
Q3 25
$-395.3K
$-76.9M
Q2 25
$3.2M
$-99.9M
Q1 25
$2.5M
$-149.7M
Q4 24
$-6.7M
$-86.2M
Q3 24
$-25
$-86.1M
Q2 24
$1.8M
$-59.2M
Q1 24
$-601.0K
$-123.2M
FCF Margin
CPHC
CPHC
NTLA
NTLA
Q4 25
-4.9%
-301.6%
Q3 25
-2.2%
-558.2%
Q2 25
20.5%
-701.0%
Q1 25
19.1%
-900.1%
Q4 24
-55.9%
-669.4%
Q3 24
-0.0%
-945.2%
Q2 24
11.1%
-850.9%
Q1 24
-4.3%
-425.7%
Capex Intensity
CPHC
CPHC
NTLA
NTLA
Q4 25
4.1%
0.5%
Q3 25
9.0%
0.2%
Q2 25
7.5%
1.7%
Q1 25
6.5%
4.4%
Q4 24
32.6%
7.6%
Q3 24
11.8%
14.0%
Q2 24
22.2%
14.5%
Q1 24
15.7%
8.7%
Cash Conversion
CPHC
CPHC
NTLA
NTLA
Q4 25
Q3 25
2.56×
Q2 25
Q1 25
Q4 24
Q3 24
1.12×
Q2 24
15.95×
Q1 24
1.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CPHC
CPHC

Casino$9.5M76%
Other$1.9M15%
Food And Beverage$1.0M8%

NTLA
NTLA

Avencell Therapeutics Inc$21.0M91%
Other$1.0M4%
Avencell$1.0M4%

Related Comparisons